Gabriella Landi

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients

Gerardo Botti, Francesca Collina, Giosuè Scognamiglio et al. · International Journal of Molecular Sciences · 2017 · 112 citations · Full text

Medicine, Immunology, Oncology +17

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial

Emanuela Rossi, Alessandro Morabito, Francesca Di Rella et al. · Journal of Clinical Oncology · 2009 · 80 citations

Medicine, Endocrinology, Oncology +17

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

Francesco Perrone, Michelino De Laurentiis, Sabino De Placido et al. · European Journal of Cancer · 2019 · 70 citations

Medicine, Gynecology, Oncology +17

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast

A. De Matteis, Francesco Nuzzo, Giuseppe D’Aiuto et al. · Cancer · 2002 · 56 citations · Full text

Medicine, Oncology, Pharmacology +15